Genetic testing for intellectual disability is not one test. It is a coordinated evaluation that may include chromosomal microarray, exome or genome sequencing, and targeted studies such as fragile X testing. The best starting point depends on the person’s age, developmental pattern, physical findings, family history, and tests already completed. A chromosomal microarray looks for missing or extra stretches of DNA, while exome sequencing reads the protein-coding portions of thousands of genes. Modern guidance increasingly supports early exome or genome sequencing for unexplained developmental delay or intellectual disability, often alongside or after microarray because the methods find different types of changes. A diagnosis can guide medical screening, therapies, recurrence-risk counseling, and access to condition-specific resources. Results can also be uncertain or negative. They should be interpreted in the context of a detailed clinical evaluation, preferably with samples from both biological parents when sequencing is performed.
- Chromosomal microarray detects many deletions and duplications but usually not single-letter gene variants.
- Exome sequencing evaluates thousands of coding genes and is most informative as a child-parent trio.
- Fragile X and other repeat or methylation disorders may require separate targeted tests.
- A pathogenic result may change health surveillance even when it does not change the disability itself.
- A variant of uncertain significance is not a diagnosis and should not direct major medical decisions alone.
- A negative result can become informative later through reanalysis or newer testing methods.
Table of Contents
- Why genetic evaluation is offered
- Choosing the right tests
- What chromosomal microarray finds
- How exome and genome sequencing work
- Targeted tests that may still be needed
- Understanding result categories
- What a diagnosis can change
- Negative results and next steps
Why genetic evaluation is offered
Intellectual disability describes significant limitations in intellectual functioning and everyday adaptive skills that begin during development. In young children, clinicians may use the term global developmental delay when progress is substantially delayed in two or more areas, such as language, movement, learning, social interaction, or self-care. Neither term identifies a cause. Genetic conditions are one important group of causes, alongside prenatal exposures, complications around birth, infections, brain injuries, and other medical factors.
A genetic evaluation begins with the person, not the laboratory menu. The clinician documents prenatal and birth history, developmental milestones, growth, seizures, behavior, sleep, feeding, hearing, vision, neurologic findings, and any loss of previously acquired skills. A three-generation family history can reveal recurrent miscarriages, learning problems, autism, epilepsy, congenital anomalies, psychiatric disease, early deaths, or relatives with similar features. Physical examination may identify a growth pattern, skin finding, head-size difference, congenital anomaly, or combination of features that points toward a specific syndrome.
Finding a molecular cause can end years of repeated testing and replace a broad label with a defined condition. It may explain why the disability occurred, clarify whether it is likely to remain stable or change, identify associated health risks, and provide a recurrence estimate for parents and adult relatives. The diagnosis can also connect a family with targeted educational resources, advocacy groups, research, and other people living with the same condition.
Testing is appropriate even when there are no unusual facial features or birth defects. Many gene-related neurodevelopmental conditions have subtle or variable physical findings. A genetic cause can also be present when pregnancy and delivery included complications; one does not necessarily exclude the other.
The evaluation should not delay early-intervention services, school supports, speech therapy, occupational therapy, behavioral care, or treatment of seizures and other current needs. Genetic testing and supportive care proceed in parallel. The goal is not to predict a child’s worth or potential. It is to obtain medically useful information while respecting the person’s dignity, strengths, communication style, and family priorities.
Choosing the right tests
Current practice often places exome or genome sequencing early in the evaluation of unexplained developmental delay, intellectual disability, or congenital anomalies. Chromosomal microarray remains valuable because it is highly validated for copy-number changes and may detect findings that an exome assay does not reliably capture. Some centers order microarray and sequencing together; others begin with sequencing and add microarray based on the platform, insurance rules, phenotype, and local expertise. There is no universal sequence that fits every person.
A practical plan considers which variant types are plausible and which the chosen laboratory can detect. The main options include:
| Test | Main changes detected | Important gaps |
|---|---|---|
| Chromosomal microarray | Submicroscopic deletions and duplications; some large regions of homozygosity; selected mosaic changes | Most single-gene sequence variants, balanced rearrangements, many repeat expansions, methylation changes |
| Exome sequencing | Variants in protein-coding regions of thousands of genes; some laboratories also report copy-number changes | Many noncoding variants, repeat expansions, methylation disorders, some structural and mosaic variants |
| Genome sequencing | Coding and noncoding sequence variants plus broader structural-variant detection, depending on validation | Some repeats, methylation, low-level mosaicism, and difficult genomic regions can still be missed |
| Targeted test | A specific repeat, methylation pattern, gene, biochemical marker, or chromosome question | Usually does not evaluate unrelated causes |
The clinician may choose a targeted test first when the presentation strongly suggests a recognizable condition. For example, a specific biochemical profile, characteristic regression pattern, family inheritance pattern, or classic physical combination can make a focused assay faster and easier to interpret. However, narrow serial testing is inefficient when dozens or hundreds of disorders fit equally well.
The laboratory’s scope matters. “Exome” is not identical across companies. Coverage, copy-number calling, mitochondrial DNA analysis, repeat detection, mosaic sensitivity, and reanalysis policies vary. The order should specify the phenotype in detail because laboratories use clinical information to prioritize variants. Terms such as “developmental delay” alone are less useful than a structured list that includes absent speech, microcephaly, epilepsy onset, movement disorder, growth pattern, and imaging findings.
Testing a child with both biological parents is called trio sequencing. It helps determine whether a variant arose newly in the child, was inherited, or consists of two changes inherited from different parents. This often improves interpretation and can reduce the number of uncertain findings. When one or both parents are unavailable, sequencing remains possible, but additional family samples may later be requested.
What chromosomal microarray finds
Chromosomal microarray examines DNA markers across all chromosomes to identify copy-number variants. A deletion means a stretch of DNA is missing; a duplication means extra material is present. These changes may include part of one gene, several genes, or a much larger chromosome segment. Microarray can detect changes too small to see on a standard karyotype.
The report describes the chromosome coordinates, size, genes involved, and classification. A pathogenic deletion or duplication is known to cause disease. A likely pathogenic result has strong evidence but slightly less certainty. Some copy-number variants are benign population differences. Others are variants of uncertain significance because available cases, inheritance data, and gene knowledge do not yet show whether the change explains the person’s features.
Parental testing can be decisive. A deletion that occurred de novo, meaning newly in the child, may support pathogenicity. An inherited change can still be disease-causing because some conditions have variable expression or incomplete penetrance, but inheritance from a healthy parent may reduce concern for certain variants. The laboratory and genetics team interpret inheritance together with size, gene content, published evidence, and the child’s phenotype.
Single-nucleotide polymorphism microarrays may also show long regions where both chromosome copies are genetically similar. This can suggest that the biological parents share ancestry, reveal uniparental disomy in certain settings, or help identify a recessive condition. Such findings can have sensitive family implications and need careful explanation. A microarray does not directly diagnose every recessive disease within a homozygous region; sequencing may still be necessary to find the causal variant.
Microarray generally does not detect a balanced translocation or inversion because no DNA is gained or lost. A karyotype may be appropriate when the family has recurrent pregnancy losses, infertility, or a known balanced chromosome rearrangement. Microarray also does not reliably detect most single-letter variants, small insertions or deletions, repeat expansions, or epigenetic changes. A normal microarray therefore does not rule out a genetic cause.
When a clinically important copy-number variant is found, the result may provide a syndrome name or describe a unique genomic change. Some larger variants affect multiple genes and produce a broad range of outcomes, so published averages cannot define one person’s future. Follow-up should focus on evidence-based screening and the individual’s actual strengths and needs.
How exome and genome sequencing work
Exome sequencing reads most exons, the protein-coding parts of genes. Although exons represent only a small portion of all DNA, many known disease-causing variants occur there. The laboratory compares the person’s sequence with a reference, filters a very large number of differences, and evaluates variants in genes that could fit the clinical features and inheritance pattern. A whole-exome sequencing test is broad, but it is still a clinically interpreted assay rather than a complete reading of every DNA base.
Genome sequencing covers coding and noncoding DNA more evenly and can detect a wider range of structural changes on some platforms. Its practical advantage depends on the laboratory’s validated analysis. A genome test that reports sequence variants but does not robustly analyze repeats, copy-number changes, mitochondrial DNA, or methylation may still require companion tests. “Whole genome” should not be understood as “finds every genetic condition.”
Exome and genome results are strongly shaped by phenotype information. A laboratory may identify thousands of rare variants, but only a small number are plausible for the person’s presentation. Accurate clinical terms help analysts connect a gene with features such as infantile spasms, severe speech impairment, hypotonia, hand stereotypies, ataxia, or progressive loss of skills. Updating the laboratory when new findings appear can change interpretation.
Trio analysis is especially useful for intellectual disability because many severe neurodevelopmental conditions are caused by a de novo variant not present in either parent. Other diagnoses are autosomal recessive, requiring one pathogenic variant from each parent in the same gene. X-linked conditions may affect people differently depending on sex chromosomes, X-inactivation, and the particular gene. Some variants are inherited from a mildly affected or apparently unaffected parent due to variable expression.
The test may include an option for secondary findings. These are pathogenic variants in a defined set of genes associated with medically actionable conditions unrelated to the reason for testing, such as certain hereditary cancer or heart conditions. Consent policies differ, and parents should understand whether they can opt in or out, whether findings are sought in the child and parents, and what follow-up may be recommended.
Exome sequencing can sometimes detect copy-number variants, but performance varies by size and genomic region. It may miss a variant in an exon with poor coverage, a deep intronic change, a complex structural rearrangement, low-level mosaicism, or an expansion in repetitive DNA. A negative exome is therefore a statement about what the assay and current knowledge did not identify, not proof that the condition is non-genetic.
Targeted tests that may still be needed
Broad sequencing does not replace every specialized assay. Fragile X syndrome is caused by a CGG repeat expansion and methylation change in FMR1. Standard exome sequencing usually does not measure that repeat correctly, so a separate fragile X test may be offered, particularly when unexplained intellectual disability, autism, characteristic behavior or physical findings, or a suggestive family history is present. Testing practices differ by sex, phenotype, and guideline.
Methylation studies are required for disorders in which gene activity depends on the parent of origin. Prader-Willi syndrome and Angelman syndrome are important examples. A sequence result alone may not show whether a critical region has the expected maternal or paternal methylation pattern. Similarly, some imprinting disorders require methylation analysis, copy-number testing, and studies for uniparental disomy in a planned sequence.
Repeat expansion disorders, mitochondrial disease, and low-level mosaic conditions may also need dedicated testing. If a child has developmental regression, episodic illness, exercise intolerance, unusual lactate findings, or organ involvement, the team may consider mitochondrial DNA analysis and biochemical studies. Skin, muscle, buccal cells, or another tissue can occasionally be more informative than blood when mosaicism is suspected.
Metabolic testing is not a single universal panel. It is selected urgently when there are red flags such as developmental regression, episodic confusion, recurrent vomiting, unexplained acidosis, unusual odors, movement crises, organ enlargement, coarse facial change, or worsening during fasting or illness. Some metabolic disorders are treatable, so clinical urgency matters more than waiting for a broad sequencing result.
Brain imaging, hearing and vision assessment, thyroid testing, lead testing, sleep evaluation, and other non-genetic studies may be indicated based on history and examination. Genetic testing should not become a reason to overlook acquired or treatable causes.
A recognizable phenotype may justify single-gene analysis or a focused panel. A panel can provide deeper coverage of selected genes and may include deletion/duplication analysis or special regions that exome does not handle well. However, broad phenotypic overlap means a negative narrow panel often leads to exome or genome sequencing later. The team should consider whether the focused test offers a meaningful technical advantage before choosing it.
Understanding result categories
A positive or diagnostic result identifies one or more pathogenic or likely pathogenic variants that explain the person’s condition. The report should name the gene or genomic region, describe the inheritance pattern, and state how well the finding matches the phenotype. “Likely pathogenic” is generally considered actionable in the same clinical way as pathogenic, although the evidence is not absolute.
A variant of uncertain significance, or VUS, means the evidence is insufficient to classify a change as disease-causing or benign. It should not be treated as a confirmed explanation, used for predictive testing in healthy relatives, or become the sole basis for major treatment or reproductive decisions. Parental testing, additional affected relatives, biochemical results, or future research may help reclassify it. Most uncertain variants are not upgraded to pathogenic, so families should not assume that uncertainty means “probably positive.” A clear genetic variant result explanation can prevent unnecessary alarm.
A negative result means no reportable cause was found with the test performed. It does not exclude a genetic disorder. The causal variant may be in a region the assay did not cover, be a type the method cannot detect, involve a gene not yet linked to disease, or remain hidden because the person’s clinical description was incomplete. Some laboratories also use “inconclusive” when one suspicious variant is found in a recessive gene but a required second variant is missing.
A secondary finding is medically important but unrelated to intellectual disability. It should be confirmed and managed according to the associated condition, often with testing of adult relatives. Carrier findings may also be reported depending on laboratory policy. Carrier status usually does not explain a dominant neurodevelopmental presentation but can matter for future reproductive planning.
A result may be only partially explanatory. For example, a pathogenic variant may account for epilepsy and developmental delay but not an unusual kidney condition. Some people have more than one diagnosis. Clinicians should avoid forcing every feature into the first molecular answer when important findings remain unexplained.
Reports can change. A VUS may be reclassified, a gene-disease relationship may become established, or a previously missed variant may be found during reanalysis. Families should keep a copy of the report, know which laboratory performed the test, and update their contact information with the clinic when possible.
What a diagnosis can change
The most immediate value of a diagnosis is often a condition-specific medical plan. Some genetic syndromes carry higher risks for seizures, heart rhythm problems, kidney disease, immune dysfunction, endocrine disorders, hearing loss, vision problems, feeding complications, or certain tumors. Knowing the cause can replace nonspecific testing with focused surveillance and may identify medications or procedures to avoid.
A result may affect treatment. A small but growing number of neurodevelopmental conditions have targeted therapies, dietary treatments, vitamin or cofactor supplementation, or gene-specific clinical trials. More often, the diagnosis guides symptom treatment: choosing appropriate seizure medicines, anticipating sleep or behavior patterns, monitoring swallowing, and selecting communication supports. Families should be cautious about unregulated products marketed as “precision” treatments without evidence.
The result can improve prognosis, but prognosis should be presented as a range. Published cases may overrepresent severely affected people, and newer diagnoses may have limited long-term data. Children with the same variant can differ in speech, mobility, behavior, medical complications, and independence. Individual developmental progress remains more informative than a syndrome label alone.
Recurrence risk depends on mechanism. A de novo dominant variant often means a low but not zero chance in another pregnancy because a parent can have germline mosaicism. A recessive diagnosis usually gives the same two carrier parents a 25% chance in each pregnancy. An X-linked or inherited dominant finding has different implications. A chromosomal rearrangement may require parental karyotypes. Genetic counseling translates the laboratory result into risks for the actual family rather than applying a generic percentage.
Parents sometimes fear that a genetic result assigns blame. In most cases, no one caused the variant through ordinary actions. New variants occur naturally, and inherited variants can be passed without anyone knowing they are present. Counseling should use neutral language and recognize that a result can bring relief, grief, guilt, validation, or mixed emotions.
Educational planning remains based on functional assessment. A diagnosis may support eligibility or explain a characteristic learning profile, but it does not replace individualized evaluation. Strengths, sensory needs, communication methods, behavior triggers, and adaptive skills should drive supports at home, school, and in the community.
Negative results and next steps
After a negative microarray, the next step may be trio exome or genome sequencing if it has not already been performed. After a negative exome, the team should review what the assay actually included: copy-number analysis, mitochondrial DNA, repeat expansion screening, coverage gaps, and whether parental samples were analyzed. A whole-genome sequencing test may add information, but it should be chosen for a specific expected advantage rather than simply because it is broader.
Reanalysis is one of the most useful next steps. Laboratories can reinterpret stored sequence data using new gene-disease discoveries, updated population databases, improved software, and newly documented clinical features. Many programs consider reanalysis after about one to three years or sooner if the person develops a major new feature. The optimal interval varies, and some laboratories require a new order or fee.
A genetics visit should also revisit the phenotype. Was there true developmental regression? Have seizures, movement abnormalities, unusual growth, organ disease, or distinctive imaging findings emerged? Is the original diagnosis of intellectual disability accurate, and were hearing, vision, language, and social communication assessed? New details can point to a targeted repeat, methylation, mitochondrial, metabolic, or tissue-specific test that broad blood sequencing missed.
Testing additional relatives can resolve uncertainty. An affected sibling, distantly related family member, or parent with subtle learning differences may provide segregation evidence. In selected cases, RNA studies, methylation profiling, long-read sequencing, optical genome mapping, or research enrollment may be useful. These approaches are not universally available and should be selected by specialists familiar with the suspected mechanism.
Families should continue recommended medical and developmental care even without a molecular name. A negative result does not invalidate the person’s needs or the family’s observations. The clinical diagnoses of intellectual disability, autism, epilepsy, or cerebral palsy remain meaningful and support appropriate services.
Before any new test, ask what it can detect, what it misses, whether parental samples are needed, how uncertain and secondary findings are handled, whether data will be reanalyzed, and how results will change care. A thoughtful testing strategy is more valuable than accumulating disconnected reports. The aim is a reliable explanation when possible and a clear, supportive plan whether the result is positive, uncertain, or negative.
References
- Genetic Evaluation of the Child With Intellectual Disability or Global Developmental Delay: Clinical Report (2025, American Academy of Pediatrics)
- Exome and Genome Sequencing for Pediatric Patients With Congenital Anomalies or Intellectual Disability: An Evidence-Based Clinical Guideline of the American College of Medical Genetics and Genomics (2021)
- A Meta-analysis of Diagnostic Yield and Clinical Utility of Genome and Exome Sequencing in Pediatric Rare and Undiagnosed Genetic Diseases (2025)
- Combining Chromosomal Microarray and Clinical Exome Sequencing for Genetic Diagnosis of Intellectual Disability (2023)
- Beyond the Exome: What’s Next in Diagnostic Testing for Mendelian Conditions (2023)
Disclaimer
This article provides general educational information and is not a substitute for individualized medical, developmental, or genetic care. Test selection and interpretation depend on the person’s history, examination, family structure, laboratory methods, and local guidance. Discuss results with a qualified clinician or genetic counselor before changing treatment, surveillance, or reproductive plans.
